AUA 2024: Updates in Prevention, Diagnostics and Surgery: PSMA PET updates
AUA 2024 prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in prostate cancer, Australian PRIMARY trial, PSMA-PET/US fusion-guided biopsy.
AUA 2024 prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in prostate cancer, Australian PRIMARY trial, PSMA-PET/US fusion-guided biopsy.
At the 2024 UCSF-UCLA PSMA Conference, Amar Kishan presents on metastasis-directed therapy (MDT) for oligometastatic prostate cancer, highlighting its potential to delay systemic therapy and…
While opponents can still file legal challenges for another month, South Dakota is now the fourth state to put the abortion issue directly before voters…
His work helped identify — and eliminate from much of the world — a disease that can cause catastrophic birth defects and fetal death.
Doctors said that a 1.9% increase for each patient brought in last month was not enough.
Localities seeking to rethink the way they handle behavioral health crises also face a variety of barriers, from developing and financing these enhanced approaches to…
At the 2024 UCSF-UCLA PSMA Conference, Louise Emmett explores the interaction between PSMA and androgen receptors in prostate cancer, focusing on their role across different…
Sam Chang engages with Jennifer Linehan to discuss topical chemotherapy for upper tract urothelial carcinoma, particularly utilizing UGN-101 (Jelmyto). Dr. Linehan shares her invaluable insights…
Ruchika Talwar hosts Yash Shah and Mihir Shah, a urologist from Jefferson in Philadelphia. They delve into their innovative research on the Utility of Artificial…
Sam Chang interviews Michiel Van der Heijden about the results of the EV-302 trial, comparing enfortumab vedotin plus pembrolizumab (EVP) against chemotherapy in previously untreated…